{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:46:00Z","timestamp":1740174360086,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40801-023-00384-0","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:02:03Z","timestamp":1695394923000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Pregnancy Outcomes Following Exposure to Intramuscular Interferon Beta-1a: The AVONEX\u00ae Pregnancy Exposure Registry"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00168714","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bianca","family":"Weinstock-Guttman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy Perrin","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Planton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avni","family":"Pandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achint","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Everage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-2781","authenticated-orcid":false,"given":"Megan","family":"Vignos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"1","key":"384_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3\u201313.","journal-title":"Rev Neurol (Paris)."},{"issue":"1","key":"384_CR2","first-page":"3","volume":"29","author":"H Gilmour","year":"2018","unstructured":"Gilmour H, Ramage-Morin PL, Wong SL. Multiple sclerosis: prevalence and impact. Health Rep. 2018;29(1):3\u20138.","journal-title":"Health Rep"},{"issue":"10","key":"384_CR3","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340.","journal-title":"Neurology"},{"key":"384_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.697974","volume":"12","author":"IL Simone","year":"2021","unstructured":"Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12: 697974.","journal-title":"Front Neurol"},{"key":"384_CR5","first-page":"1","volume":"12","author":"R Villaverde-Gonz\u00e1lez","year":"2022","unstructured":"Villaverde-Gonz\u00e1lez R. Updated perspectives on the challenges of managing multiple sclerosis during pregnancy. Degener Neurol Neuromuscul Dis. 2022;12:1\u201321.","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"384_CR6","unstructured":"Biogen Inc. Avonex US prescribing information. 2021. https:\/\/hcp.avonex.com\/content\/dam\/commercial\/avonex\/hcp\/en_us\/pdf\/Avonex_US_Prescribing_Information.pdf. Accessed 22 Apr 2023."},{"issue":"6","key":"384_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/1352458516634872","volume":"22","author":"S Thiel","year":"2016","unstructured":"Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis: a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22(6):801\u20139.","journal-title":"Mult Scler"},{"issue":"6","key":"384_CR8","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00415-020-09762-y","volume":"267","author":"K Hellwig","year":"2020","unstructured":"Hellwig K, Geissbuehler Y, Sabid\u00f3 M, Popescu C, Adamo A, Klinger J, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol. 2020;267(6):1715\u201323.","journal-title":"J Neurol"},{"key":"384_CR9","doi-asserted-by":"publisher","first-page":"175628642095107","DOI":"10.1177\/1756286420951072","volume":"13","author":"KM Hakkarainen","year":"2020","unstructured":"Hakkarainen KM, Juuti R, Burkill S, Geissbuhler Y, Sabido M, Popescu C, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020;13:1756286420951072.","journal-title":"Ther Adv Neurol Disord"},{"key":"384_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102694","volume":"48","author":"M Korjagina","year":"2021","unstructured":"Korjagina M, Hakkarainen KM, Burkill S, Geissbuhler Y, Sabido M, Everage N, et al. Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden. Mult Scler Relat Disord. 2021;48: 102694.","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"384_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","volume":"23","author":"KM Krysko","year":"2021","unstructured":"Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):11.","journal-title":"Curr Treat Options Neurol"},{"key":"384_CR12","doi-asserted-by":"crossref","unstructured":"Varyte G, Zakareviciene J, Ramasauskaite D, Lauzikiene D, Arlauskiene A. Pregnancy and multiple sclerosis: an update on the disease modifying treatment strategy and a review of pregnancy's impact on disease activity. Medicina (Kaunas). 2020;56(2):49.","DOI":"10.3390\/medicina56020049"},{"issue":"9","key":"384_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/bdra.10111","volume":"67","author":"A Correa-Villasenor","year":"2003","unstructured":"Correa-Villasenor A, Cragan J, Kucik J, O\u2019Leary L, Siffel C, Williams L. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol. 2003;67(9):617\u201324.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"384_CR14","first-page":"65","volume":"79","author":"A Correa","year":"2007","unstructured":"Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al. Reporting birth defects surveillance data 1968\u20132003. Birth Defects Res A Clin Mol Teratol. 2007;79(2):65\u2013186.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"384_CR15","unstructured":"Centers for Disease Control and Prevention (CDC). Metropolitan Atlanta Congenital Defect Program (MACDP) six-digit code defect list, version 08\/07. 2007."},{"issue":"6","key":"384_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/pds.726","volume":"11","author":"A Scheuerle","year":"2002","unstructured":"Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf. 2002;11(6):465\u201375.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"384_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/bdra.20434","volume":"82","author":"A Correa","year":"2008","unstructured":"Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al. Erratum. Birth Defects Res A Clin Mol Teratol. 2008;82(1):41\u201362.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"384_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/0471445428","volume-title":"Statistical methods for rates and proportions","author":"J Fleiss","year":"2003","unstructured":"Fleiss J, Levin B, Paik M. Statistical methods for rates and proportions. 3rd ed. Hoboken: Wiley; 2003.","edition":"3"},{"key":"384_CR19","unstructured":"US Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. In: US Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, editors. Rockville: US Food and Drug Administration; 2002."},{"issue":"2","key":"384_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.1471","volume":"17","author":"International Society for Pharmacoepidemiology (ISPE)","year":"2008","unstructured":"International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices. Pharmacoepidemiol Drug Saf. 2008;17(2):200\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"384_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical A","year":"2013","unstructured":"World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"384_CR22","unstructured":"Centers for Disease Control and Prevention. Data table of infant head circumference-for-age charts. 2001 August 23, 2001. https:\/\/www.cdc.gov\/growthcharts\/html_charts\/hcageinf.htm. Accessed 15 Jun 2023."},{"issue":"7251","key":"384_CR23","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"AM Nybo Andersen","year":"2000","unstructured":"Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708\u201312.","journal-title":"BMJ"},{"issue":"1","key":"384_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/146642408710700114","volume":"107","author":"CC Anokute","year":"1987","unstructured":"Anokute CC. Epidemiology of spontaneous abortions: the effect of previous abortions. J R Soc Health. 1987;107(1):31\u20133.","journal-title":"J R Soc Health"},{"issue":"9","key":"384_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/1352458509106543","volume":"15","author":"C Weber-Schoendorfer","year":"2009","unstructured":"Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15(9):1037\u201342.","journal-title":"Mult Scler"},{"key":"384_CR26","volume-title":"Hypospadias","author":"AE Donaire","year":"2023","unstructured":"Donaire AE, Mendez MD. Hypospadias. Treasure Island: StatPearls; 2023."},{"key":"384_CR27","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/bdra.20780","volume":"91","author":"PA Boyd","year":"2011","unstructured":"Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: the EUROCAT network: organization and processes. Birth Defects Res A Clin Mol Teratol. 2011;91:S2-15.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"6","key":"384_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1212\/01.wnl.0000168905.97207.d0","volume":"65","author":"M Sandberg-Wollheim","year":"2005","unstructured":"Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005;65(6):802\u20136.","journal-title":"Neurology"},{"issue":"6","key":"384_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/01.wnl.0000180575.77021.c4","volume":"65","author":"R Boskovic","year":"2005","unstructured":"Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005;65(6):807\u201311.","journal-title":"Neurology"},{"issue":"8","key":"384_CR30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00415-008-0909-4","volume":"255","author":"F Patti","year":"2008","unstructured":"Patti F, Cavallaro T, Lo Fermo S, Nicoletti A, Cimino V, Vecchio R, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol. 2008;255(8):1250\u20133.","journal-title":"J Neurol"},{"issue":"3","key":"384_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00415-010-5758-2","volume":"258","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258(3):502\u20133.","journal-title":"J Neurol"},{"issue":"20","key":"384_CR32","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","volume":"75","author":"MP Amato","year":"2010","unstructured":"Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology. 2010;75(20):1794\u2013802.","journal-title":"Neurology"},{"issue":"5","key":"384_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004536","volume":"4","author":"PK Coyle","year":"2014","unstructured":"Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM Jr, Albano JD, Rametta MJ. Final results from the Betaseron (interferon \u03b2-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4(5): e004536.","journal-title":"BMJ Open"},{"issue":"4","key":"384_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1352458510394610","volume":"17","author":"M Sandberg-Wollheim","year":"2011","unstructured":"Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17(4):423\u201330.","journal-title":"Mult Scler"},{"key":"384_CR35","first-page":"182","volume":"28","author":"N Friedmann","year":"2022","unstructured":"Friedmann N, Ciplea AI, Thiel S, Gold R, Hellwig K. Interferon- or peginterferon-beta 1a exposure during pregnancy in women with multiple sclerosis: outcomes on child development. Mult Scler. 2022;28:182.","journal-title":"Mult Scler"},{"key":"384_CR36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/13524585211011390","volume":"28","author":"Y Begus-Nahrmann","year":"2022","unstructured":"Begus-Nahrmann Y, Taipale K, Niemczyk G, Rehberg-Weber K, Klehmet J. Interferon beta exposure during pregnancy and breastfeeding: impact on birth outcome and child development: results from the post-authorisation safety study PRIMA. Mult Scler. 2022;28:463.","journal-title":"Mult Scler"},{"issue":"2S","key":"384_CR37","first-page":"656","volume":"27","author":"MS-WK Sabid\u00f3","year":"2021","unstructured":"Sabid\u00f3 MS-WK, Grimes N, Prach LM, Zhao L, Hakkarainen KM. Interferon beta exposure in the 2nd and 3rd trimester of pregnancy a register based drug utilisation study in Finland and Sweden. Mult Scler. 2021;27(2S):656.","journal-title":"Mult Scler"},{"issue":"1","key":"384_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s10194-022-01533-6","volume":"23","author":"HM Crowe","year":"2022","unstructured":"Crowe HM, Wesselink AK, Wise LA, Jick SS, Rothman KJ, Mikkelsen EM, et al. Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study. J Headache Pain. 2022;23(1):162.","journal-title":"J Headache Pain"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00384-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T23:07:30Z","timestamp":1703027250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00384-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00384-0","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"9 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Biogen (Cambridge, MA, USA) sponsored this study and provided funding for medical writing support in the development of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bianca Weinstock-Guttman has participated in speaker\u2019s bureaus and\/or served as a consultant for, and\/or received grant\/research support from Biogen, EMD Serono, Novartis, Genentech, Celgene\/Bristol Myers Squibb, Sanofi Genzyme, Bayer, Janssen, Labcorp, and Horizon. She serves on the editorial board of <i>BMJ Neurology<\/i>, <i>Children<\/i>, <i>CNS Drugs<\/i>, <i>MS International<\/i>, and <i>Frontiers Epidemiology<\/i>. Amy Perrin Ross has acted as a consultant for Biogen, EMD Serono, Novartis, Celgene\/BMS, Roche, Sanofi Genzyme, Genentech, Janssen, Horizon, and Alexion. Jonathan Planton, Kurt White, Avni Pandhi, Andres Greco, Achint Kumar, Nicholas Everage, and Megan Vignos are employees of and may hold stock\/stock options in Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The registry obtained central institutional review board approval for the study protocol and all amendments, which were performed in accordance with FDA guidance \u201cEstablishing Pregnancy Exposure Registries,\u201d the International Society for Pharmacoepidemiology\u2019s Guidelines for Good Pharmacoepidemiology Practices, and the ethical principles outlined in the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Verbal informed consent was obtained from participants in accordance with local practice and regulations. During the initial telephone encounter, participants were asked to provide verbal consent to enroll and to provide authorization for their healthcare providers, including their infant\u2019s pediatrician, to release medical information to the registry.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The trial is registered on ClinicalTrials.gov (NCT00168714). Request for the data supporting this manuscript should be submitted to .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"In addition to the contributions listed below, all authors read and approved the final version. BW-G, APR, JP, NE: analysis and interpretation of the data and drafting\/critically revising the manuscript; KW, AP, AG, AK: collection of the data, analysis and interpretation of the data, and drafting\/critically revising the manuscript; MV: post-hoc plan of statistical analyses, analysis and interpretation of the data, and drafting\/critically revising the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}